RxDoctor Payments Data

Josephine Perez, MD

Family Medicine · Kingsburg, CANPI 1477618650

Payments from drug & device makers

$1,184in general payments, 2019–2025

Across 46 payments — averaging $25.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$383
  • Kowa Pharmaceuticals America, Inc.$348
  • Lilly USA, LLC$112
  • Novo Nordisk$105
  • Exact Sciences$36
  • Johnson & Johnson$34
  • plus $167 from 9 others

What the payments were for

  • Food & beverage$1,184100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,184 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$88,675
Medicare patients
247
Services billed
1,286

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide47$63,766
JardianceEmpagliflozin32$44,464
TrulicityDulaglutide29$41,442
EliquisApixaban26$34,329
JanuviaSitagliptin Phosphate26$25,342
Repatha SureclickEvolocumab36$24,998
LinzessLinaclotide22$13,173
GemtesaVibegron20$13,048
VascepaIcosapent Ethyl11$6,562
Spiriva HandihalerTiotropium Bromide13$6,330
LivaloPitavastatin Calcium11$5,863
Breo ElliptaFluticasone/Vilanterol13$5,047
Levothyroxine Sodium270$4,151
Atorvastatin Calcium310$3,699
Rosuvastatin Calcium142$3,594

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$105$63,76647 claims
Lilly USA, LLCTrulicity$112$41,44229 claims
PfizerEliquis$15$34,32926 claims
AbbVieLinzess$15$13,17322 claims
Sumitomo Pharma America, Inc.Gemtesa$21$13,04820 claims
Kowa Pharmaceuticals America, Inc.Livalo$348$5,86311 claims
GSKBreo Ellipta$22$5,04713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in Kingsburg

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →